key: cord-0799280-63lhdybb
authors: Liotta, Eric M.; Batra, Ayush; Koralnik, Igor J.
title: Reply to COVID‐19 encephalopathy, Bayes rule, and a plea for case–control studies
date: 2021-01-29
journal: Ann Clin Transl Neurol
DOI: 10.1002/acn3.51287
sha: bdf38c1548098655ae60b2c0d31738fcc3691bf4
doc_id: 799280
cord_uid: 63lhdybb

nan

We thank Arbona-Haddad and colleagues for their interest in our study of the neurologic manifestations of Covid-19 in the first 509 patients hospitalized in our hospital network system. 1, 2 By reanalyzing our data using a Bayesian approach, they came to a similar conclusion regarding the high frequency of encephalopathy in patients with severe Covid-19 disease requiring mechanical ventilation.

Their opinion that Covid-19 suspected cases admitted during the same period with a negative test result could serve as acceptable controls is interesting. However, these control subjects would include a heterogenous population of patients with numerous other viral infections, sepsis, febrile illnesses, respiratory, and neurologic diseases, complicating their use as feasible controls. In addition, these individuals would also potentially include Covid-19 patients with false negative test results.

As the entire country is witnessing a surge of infections, neurologists will be on the frontlines to diagnose and manage the multiple neurologic manifestations of Covid-19. Neurologists will also play a critical role in the pandemic recovery as the neurologic consequences of Covid-19 appear to linger long after the resolution of the pulmonary manifestations.

Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients

Covid-19 encephalopathy, Bayes rule, and the plea for casecontrol studies

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium

None.